Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System.

Area of Science:

• Cardiology
• Medical Devices
• Electrophysiology

Background:

• The subcutaneous implantable cardioverter-defibrillator (S-ICD) system was developed to mitigate risks associated with transvenous leads.
• Previous studies demonstrated S-ICD safety and efficacy in select patient groups or with limited follow-up.

Purpose of the Study:

• To evaluate the long-term safety and efficacy of the S-ICD system in a broad and diverse patient population.
• To assess device performance across numerous U.S. implantation centers through a real-world registry.

Main Methods:

• Prospective enrollment of 1,643 patients across 86 U.S. centers meeting standard S-ICD indications.
• Observation for up to 5 years, assessing primary endpoints of shock efficacy and system-related complications.
• Utilized prespecified performance goals to evaluate safety and efficacy endpoints.

Main Results:

• Achieved high shock efficacy (98.4%) for ventricular arrhythmias, consistent throughout the follow-up period.
• Reported low complication rates: 93.4% S-ICD-related and 99.3% electrode-related.
• Only 1.6% of patients required conversion to a transvenous implantable cardioverter-defibrillator (TV-ICD) for pacing needs.

Conclusions:

• The S-ICD System Post Approval Study (PAS) met all prespecified endpoints, confirming 5-year safety and efficacy.
• Demonstrated low complication rates and high shock efficacy in a large, diverse patient cohort with comorbidities.
• Supports the S-ICD as a viable long-term therapeutic option for a broad range of patients.